GoodRx Holdings, Inc. (GDRX) Spending and interest coverage
- R&D / revenue · 12 months: Value 14.88%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 8.80%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 14.88% | Research and development expense / revenue. Period ending 2026-06-30. $116.84M ÷ $785.23M × 100 ≈ 14.88% |
| Stock-based compensation / revenue · 12 months | 8.80% | Share-based compensation / revenue. Period ending 2026-06-30. $69.14M ÷ $785.23M × 100 ≈ 8.80% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 116.84M USD | Research and Development Expense |
| Revenue | 785.23M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 69.14M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 74.94M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $116.84M | $785.23M | $69.14M | $74.94M | (m) | 14.88% | 8.80% | (m) | (m) |
| 2026-03-31 | $120.06M | $787.89M | $73.96M | $78.12M | (m) | 15.24% | 9.39% | (m) | (m) |
| 2025-12-31 | $121.03M | $796.85M | $76.63M | $87.49M | (m) | 15.19% | 9.62% | (m) | (m) |
| 2025-09-30 | $123.83M | $800.65M | $79.67M | $82.99M | (m) | 15.47% | 9.95% | (m) | (m) |
| 2025-06-30 | $122.95M | $799.87M | $87.93M | $88.78M | (m) | 15.37% | 10.99% | (m) | (m) |
| 2025-03-31 | $123.87M | $797.41M | $93.10M | $81.84M | (m) | 15.53% | 11.68% | (m) | (m) |
| 2024-12-31 | $123.75M | $792.32M | $99.03M | $65.85M | (m) | 15.62% | 12.50% | (m) | (m) |
| 2024-09-30 | $124.04M | $790.38M | $106.84M | $29.38M | (m) | 15.69% | 13.52% | (m) | (m) |
| 2024-06-30 | $133.51M | $775.09M | $113.11M | $-29.36M | (m) | 17.23% | 14.59% | (m) | (m) |
| 2024-03-31 | $133.94M | $764.16M | $104.42M | $-30.93M | (m) | 17.53% | 13.66% | (m) | (m) |
| 2023-12-31 | $135.84M | $750.26M | $104.82M | $-27.01M | (m) | 18.11% | 13.97% | (m) | (m) |
| 2023-09-30 | $140.57M | $737.73M | $105.46M | $-6.98M | (m) | 19.05% | 14.29% | (m) | (m) |
| 2023-06-30 | $136.88M | $745.09M | $101.85M | $15.63M | (m) | 18.37% | 13.67% | (m) | (m) |
| 2023-03-31 | $141.00M | $747.21M | $115.58M | $-6.72M | (m) | 18.87% | 15.47% | (m) | (m) |
| 2022-12-31 | $143.14M | $766.55M | $120.23M | $1.74M | (m) | 18.67% | 15.69% | (m) | (m) |
| 2022-09-30 | $141.43M | $795.70M | $124.10M | $11.76M | (m) | 17.77% | 15.60% | (m) | (m) |
| 2022-06-30 | $140.58M | $803.49M | $135.04M | $34.47M | (m) | 17.50% | 16.81% | (m) | (m) |
| 2022-03-31 | $134.74M | $788.32M | $144.09M | $38.16M | (m) | 17.09% | 18.28% | (m) | (m) |
| 2021-12-31 | $125.86M | $745.42M | $160.46M | $13.41M | (m) | 16.88% | 21.53% | (m) | (m) |
| 2021-09-30 | $114.48M | $685.71M | $413.26M | $-297.79M | (m) | 16.70% | 60.27% | (m) | (m) |
| 2021-06-30 | $95.26M | $631.06M | $480.16M | $-366.47M | (m) | 15.09% | 76.09% | (m) | (m) |
| 2021-03-31 | $77.65M | $577.72M | $441.60M | $-324.39M | (m) | 13.44% | 76.44% | (m) | (m) |
| 2020-12-31 | $61.82M | $550.70M | $397.29M | $-275.72M | (m) | 11.22% | 72.14% | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $29.30M | $388.22M | $3.75M | $139.68M | (m) | 7.55% | 0.97% | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $43.89M | $249.52M | $1.76M | $77.25M | (m) | 17.59% | 0.71% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.